Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia

Pediatric Blood and Cancer

Volumn 62, Issue 3, 2015, Pages 477-482

  Cies, Jeffrey J ^a,b,c   Jain, Jaimi ^d   Kuti, Joseph L ^d  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotic dosing; Febrile neutropenia; Pediatric; Pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACCURACY; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; FEVER; NEOPLASMS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84921419399     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25287     Document Type: Article

References (43)

1. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, Dupuis LL, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli S, Steinbach WJ, Villarroel M, Zaoutis T, Sung L. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427-4438.
2. Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines: Children are not little adults. Eur J Cancer 2011; 47:811-813.
3. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Arico M, Castagnola E. Infection Study Group of the Associazione Italiana Ematologica Oncologia Pediatrica (AIEOP). Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010; 95:1612-1615.
4. Daenen S, Erjavec Z, Uges DR, Vries HG-Hospers, Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:188-192.
5. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leede JS, Kauffman RE. Developmental pharmacology-Drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.
6. Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis 2012; 54:1785-1792.
7. Navas D, Caillon J, Batard E, Le Conte P, Kergueris MF, Moreau P, Potel G. Trough serum concentrations of beta-lactam antibiotics in cancer patients: Inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 2006; 27:102-107.
8. Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49:3550-3553.
9. Krivoy N, Peleg S, Postovsky S, Ben Arush MW. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol 1998; 15:333-338.
10. Silva DC, Seixas GT, Araujo OR, Arduini RG, Carlesse FA, Petrilli AS. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients. Braz J Infect Dis 2012; 16:361-365.
11. Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol 2011; 12:2030-2036.
12. Romano S, Fdez de Gatta MM, Calvo MV, Caballero MV, Dominquez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44:235-242.
13. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update 2011; 14:107-117.
14. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27:10-22.
15. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4:1832-1843.
16. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34:467-476.
17. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6:165-175.
18. Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007; 27:333-342.
19. Piperacillin/tazobactam (Zosyn®) [package insert]. Philadelphia, PA: Pfizer Pharmaceuticals; May 2013.
20. Lexi-Comp Online™, Hudson, Ohio: Lexi-Comp, Inc.; Accessed May 3, 2013.
21. Pediatric & Neonatal Lexi-Drugs Online™, Hudson, Ohio: Lexi-Comp, Inc. Accessed December 15, 2012.
22. Thomson Micromedex Web site. http://uspdi.micromedex.com/. Accessed December 15, 2012.
23. Barone MA, editor. The Harriet Lane handbook: A manual for pediatric house officers. 16th ed. St. Louis Mosby-Year Book 2002.
24. Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994; 38:2817-2826.
25. Delvallee M, Mazingue F, Abouchahla W, Delebarre M, Wallet F, Courcol R, Kipnes E, Dessein R. Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia. Pediatr Infect Dis J 2013; 32:962-964.
26. Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J 2014; 33:168-173.
27. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 2001; 33:222-226.
28. Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, Taniguchi K, Shimura K, Kanbayashi Y, Komori T, Matsumoto Y, Fujita N, Shimazaki C, Taniwaki M. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 2008; 61:892-900.
29. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother 2011; 17:831-841.
30. Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents 2011; 38:231-236.
31. Lee DG, Choi SM, Shin WS, Lah HO, Yim DS. cPopulation pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28:333-339.
32. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39:32-38.
33. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16:797-802.
34. Lamoth F, Buclin T, Csajka C, Pascual A, Calandra T, Marchetti O. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53:785-787.
35. Janmohamed RM, Leyland MJ, Kelly J, Farrell I. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1990; 25:407-412.
36. Drusano GL, Plaisance KI, Forrest A, Bustamante C, Devlin A, Standiford HC, Wade JC. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987; 31:1420-1422.
37. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther 1989; 45:635-641.
38. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53:379-385.
39. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003; 23:291-295.
40. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46:1171-1178.
41. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-363.
42. Dalle JH, Gnansounou Magloire, Husson MO, Lambilliotte Anne, Mazingue F, Nelken B. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediat Hemato Onc 2002; 24:714-716.
43. Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:109-116.